COMPOSITIONS AND METHODS OF USE FOR ALPHA-1 ANTITRYPSIN HAVING NO SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY
Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a bacterial infection, or a viral infection in a subject. More particularly, embodiments herein relate to compounds including naturally occurring and synthetic compositions having alpha-1 antitrypsin activity but no significant serine protease inhibitor activity.
1 . A pharmaceutical composition comprising: alpha-1 antitrypsin (AAT) having no significant serine protease inhibition activity.
2 . The pharmaceutical composition of claim 1 , wherein alpha-1 antitrypsin comprises alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof, having no significant serine protease inhibition activity.
3 . The pharmaceutical composition of claim 1 , further comprising an agent selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, an anti-microbial agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, an anti-parasitic agent or any combination thereof.
4 . The pharmaceutical composition of claim 1 , further comprising an anti-bacterial agent.
5 . A method of treating a subject with a medical disorder comprising administering to the subject in need of such a treatment a therapeutically effective amount of a composition comprising, alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof, having no significant serine protease inhibition activity.
6 . The method of claim 5 , wherein the disorder is selected from the group consisting of a viral infection, a bacterial infection, and a combination thereof.
7 . The method of claim 5 , wherein the disorder is selected from the group consisting of sepsis, septic shock, Acute Respiratory Distress Syndrome (ARDS), ajamian reperfusion, congestive heart failure, cardiac ischemia, stroke cerebral vascular, influenza, acute liver failure, chronic liver failure, a common cold, meningitis, Encephalitis, Candida or CMV esophagitis, pancreatitis, acute renal failure (ischemic, toxic, metabolic, thrombotic, due to collagen-vascular disease), cardiac ischemia (angina, yocardoal infarction), hepatitis (e.g. due to viruses like HAV/HBC/HCV/HSV/CMV/EBV or toxins/medications, autoimmune, ischemic), ischemia-reperfusion injury, ischemic or infectious colitis/enteritis, atypical mycobacteria, and hemorrhagic fevers (e.g. Ebola, Marbutg, Sin Nombre).
8 . The method of claim 6 , wherein the viral infection comprises a retroviral infection.
9 . The method of claim 8 , wherein the retrovirus infection is selected from the group consisting of human immunodeficiency virus (HIV) infection, AIDS (acquired immunodeficiency syndrome), influenza virus infection, hepatitis virus infection, Herpes virus infection and combinations thereof.
10 . The method of claim 6 , wherein the bacterial infection is selected from the group consisting of mycobacterial infection, sepsis, septic shock, bacterial meningitis, bacterial pneumonia, bacillus anthracis infection, and combinations thereof.
11 . The method of claim 10 , wherein the bacillus anthracis infection is derived from inhalation anthrax, cutaneous anthrax, gastrointestinal anthrax and combinations thereof.
12 . The method of claim 5 , wherein the composition further comprises an agent selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, an anti-viral agent, an anti-pathogenic agent, an anti-bacterial agent, a reverse transcriptase inhibitor, a protease inhibitor, and combinations thereof.
13 . The method of claim 5 , wherein the composition is administered orally, systemically, via an implant, intravenously, topically, intrathecally, by inhalation, nasally or a combination thereof.
14 . The method of claim 5 , wherein the treatment further comprises reducing or eliminating one or more symptom associated with the disorder.
15 . The method of claim 5 , wherein the viral infection is an influenza infection.
16 . A method for reducing serine protease inhibition activity in alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof comprising heating alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof at a temperature of about 85° C. to about 110° C. for about 1 minute to about 1 hour.
17 . The method of claim 16 , further comprising assessing serine protease inhibition activity of the alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof using a serine protease inhibitor activity assay.
18 . A kit comprising: a composition comprising, alpha-1 antitrypsin, a fragment thereof, an analog thereof, or fusion molecule thereof, having no significant serine protease inhibition activity; and at least one container.
19 . The kit of claim 18 , further comprising an agent selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, an anti-microbial agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, an anti-parasitic agent or any combination thereof.